Labetalol S.A.L.F. (Labetalol Hydrochloride)

Labetalol blocks both beta‑adrenergic receptors (reducing heart rate and contractility) and alpha‑1 receptors (causing vasodilation). This dual action decreases cardiac output and peripheral vascular resistance, leading to a net reduction in systemic blood pressure.

The specific dose and infusion rate of Labetalol S.A.L.F. are determined by the prescribing clinician based on the patient’s condition, severity of hypertension, and response to therapy. Dosing is individualized and should follow local clinical guidelines.

Labetalol is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It is commonly used for hypertension in pregnancy when benefits outweigh potential risks. Limited data are available for breastfeeding; clinicians should weigh benefits and risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Labetalol’s unique combination of alpha‑ and beta‑blockade provides both heart‑rate reduction and vasodilation, making it especially useful in situations where rapid blood pressure control is needed without excessive reflex tachycardia. Compared with pure beta‑blockers, it offers additional peripheral vasodilation; compared with pure vasodilators, it also reduces cardiac output.

Labetalol S.A.L.F. should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Labetalol S.A.L.F. is given as an intravenous injection or infusion. The medication is typically diluted in an appropriate compatible solution and administered under continuous blood pressure monitoring to allow rapid titration to the desired effect.

The most serious risks include severe hypotension, bronchospasm in patients with reactive airway disease, hepatic injury, and cardiac conduction disturbances such as heart block. Prompt recognition and management of these events are essential, and patients should be monitored closely during treatment.

Labetalol is contraindicated in patients with known hypersensitivity to labetalol or any component of the formulation, in those with severe bradycardia, advanced heart block without a pacemaker, and in patients with uncontrolled asthma or severe chronic obstructive pulmonary disease.